The baboon model of pertussis: effective use and lessons for pertussis vaccines

@article{Warfel2014TheBM,
  title={The baboon model of pertussis: effective use and lessons for pertussis vaccines},
  author={Jason M. Warfel and Tod J. Merkel},
  journal={Expert Review of Vaccines},
  year={2014},
  volume={13},
  pages={1241 - 1252}
}
The USA is experiencing a pertussis resurgence that resulted in a 60-year high of 48,000 cases in 2012. Our ability to counteract this resurgence is hampered by the fact that pertussis pathogenesis and immunity to pertussis infection are not well studied. Studies in humans are difficult due to the low frequency of pertussis in the population, the cyclical nature of incidence and the sporadic geographic distribution of cases. While existing animal models reproduce many aspects of pertussis, none… 
Pertussis disease and transmission and host responses: insights from the baboon model of pertussis.
TLDR
It is hoped that the knowledge gained through use of the baboon model of pertussis and clinical studies will allow the development of more efficacious vaccines, conferring long lasting protection against disease and transmission.
Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis
TLDR
Using the baboon model, immunization with any of the three whole-cell vaccines significantly accelerated the clearance of B. pertussis following challenge and determined that transcription of the gene encoding interleukin-17 (IL-17) was increased in whole- cell- vaccinated and previously infected animals but not in acellular-pertussis-vaccinated animals following challenge.
Reinvestigating the Coughing Rat Model of Pertussis To Understand Bordetella pertussis Pathogenesis
TLDR
The coughing rat model provides a way of characterizing disease manifestation differences between B. pertussis strains, and the emergence of genetically diverging strains, combined with waning aP vaccine efficacy, calls for reevaluation of current animal models of pertuss is called for.
The 112-Year Odyssey of Pertussis and Pertussis Vaccines-Mistakes Made and Implications for the Future.
  • J. Cherry
  • Medicine
    Journal of the Pediatric Infectious Diseases Society
  • 2019
TLDR
In the last 13 years, major pertussis epidemics have occurred in the United States, and numerous studies have shown the deficiencies of DTaP vaccines, including the small number of antigens that the vaccines contain and the type of cellular immune response that they elicit.
Re-investigating the coughing rat model of pertussis to understand Bordetella pertussis pathogenesis
TLDR
The coughing rat model provides a way of characterizing disease manifestation differences between Bp strains, and two genetically divergent strains Tohama 1 and D420 are compared.
What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.
TLDR
Pertussis is resurgent in some countries, particularly those in which children receive acellular pertussis (aP) vaccines in early infancy and boosters later in life, and the increase appears to be the result of waning immunity.
New Challenges for Pertussis Vaccines
TLDR
New vaccines that are both well-tolerated and highly effective with long-term protection are required but will not be available in the short term, including increased numbers of booster doses and protection of newborns through maternal immunization.
The difficult road to new vaccines for pertussis and serogroup B meningococcal disease
TLDR
The considerable uncertainties for development of third generation pertussis vaccines will be discussed along with related issues in the development of new vaccines for the prevention of serogroup B meningococcal (MenB) disease.
Investigating the pertussis resurgence in England and Wales, and options for future control
TLDR
Findings support the recent recommendation by the World Health Organisation that countries currently using wP vaccine for primary immunisation should not change to aP vaccine unless additional strategies to control infant disease such as maternal immunisation can be assured.
Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis
TLDR
Assessment of DTaP and Tdap VE estimates remain similar to those found in other settings, despite high prevalence of pertactin deficiency in Vermont, suggesting these vaccines continue to be protective against reported pertussis disease.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 101 REFERENCES
Nonhuman Primate Model of Pertussis
TLDR
The results demonstrate that the baboon provides an excellent model of clinical pertussis that will allow researchers to investigate pertussedis pathogenesis and disease progression, evaluate currently licensed vaccines, and develop improved vaccines and therapeutics.
Resurgence of pertussis calls for re-evaluation of pertussis animal models
TLDR
Pertussis has recently re-emerged in well-vaccinated populations most likely due to a combination of pathogen adaptation and waning of vaccine-induced pertussis immunity, and the scenario asks for new, improved vaccines with at least a longer duration of protection.
Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model
TLDR
The observation that aP, which induces an immune response mismatched to that induced by natural infection, fails to prevent colonization or transmission provides a plausible explanation for the resurgence of pertussis and suggests that optimal control of pertussedis will require the development of improved vaccines.
Nonhuman primate and human challenge models of pertussis.
TLDR
The recent development of a baboon model of pertussis has the potential to provide a path forward for answering critical questions about pertussedis pathogenesis and host responses and will likely aid in the development of next-generation pertussIS vaccines.
The benefits of using diverse animal models for studying pertussis.
TLDR
The various animal models available currently and their benefits for studying pertussis are reviewed, including the mouse model, which has benefited in the development of these vaccines tremendously.
Re-emergence of pertussis: what are the solutions?
TLDR
Vaccination of newborns, additional booster doses for older adolescents and adults, and immunization of pregnant women with existing vaccines are discussed and their potential impact on pertussis control assessed.
Research aims to boost pertussis control.
TLDR
While this vaccine schedule has reduced the morbidity and mortality of this deadly illness in children, the recent resurgence in whooping cough is troubling and not well understood.
Pertussis outbreaks and pertussis vaccines: new insights, new concerns, new recommendations?
TLDR
The U.S. and many other industrialized countries are experiencing continuing large-scale pertussis outbreaks, and between 43% and 76% of subjects for whom vaccination history was available were up to date on DTaP or Tdap immunization.
Waning protection after fifth dose of acellular pertussis vaccine in children.
TLDR
Pertussis waned during the 5 years after the fifth dose of DTaP, and the odds of acquiring pertussis increased by an average of 42% per year after 2006 to 2011.
Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies
TLDR
DTaP vaccines, which are less reactogenic than DTP vaccines, are now in general use in many developed countries, and it is expected that the expansion of their use to adolescents and adults will have a significant impact on reducing pertussis and perhaps decrease the circulation of B. pertussedis.
...
1
2
3
4
5
...